22-MULTI-53-KB-PMC : A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors, KN-8701

Grants and Contracts Details

StatusActive
Effective start/end date1/9/2311/30/24

Funding

  • Kinnate Biopharma Incorporated: $27,721.00